Following CMS’s preliminary decision to limit the coverage of Biogen’s Alzehimer’s disease treatment Aduhelm, advocates are calling on the agency to broaden its coverage or risk the future of similar drugs, according to a Jan. 17 Politico report.
Read the full post on Becker's Hospital Review - Healthcare News
